USE OF THE FUSION INHIBITOR ENFUVIRTIDE IN ANTIRETROVIRAL THERAPY REGIMENS FOR HIV-INFECTED PATIENTS
- Authors: Kravchenko A.V.1,2, Kanestri V.G1,2
-
Affiliations:
- Federal Scientific-and-Methodic Center for AIDS Prevention and Control
- Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
- Issue: No 1 (2013)
- Pages: 47-52
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/276448
- ID: 276448
Cite item
Open Access
Access granted
Abstract
Enfuvirtide (ENF) is the first and now only drug from a class of cellular HIV fusion inhibitors. The highest therapeutic effectiveness was obtained in patients with HIV infection resistant to a number of drugs when the antiretroviral therapy (ARVT) regimen included ENF in combination with agents from previously used classes, but having another spectrum of virus resistance mutations or in combination with new classes of antiretroviral drugs. The existing recommendations suggest that it is advisable to use ENF in patients who had received two or more ineffective therapy regimens. However, there is more and more increasing evidence for its use as a component of an ARVT regimen for some categories of HIV-infected patients. A rapider decrease in HIV RNA levels in patients taking ENF and a substantially more marked increase in the count of CD4 + lymphocytes permit the use of this drug in patients who had very low baseline CD4 + lymphocyte counts (< 50 cells/μl) and in those with comorbidity (HIV infection and tuberculosis). Physicians’ opinion about some difficulties in its intake and patients’ negative attitude towards agents to be injected is a common obstacle to the use of ENF. Comparative analysis of the opinions of physicians and patients on ENF revealed a discrepancy between the physician and patients in the perception of ENF use and showed that the patients had a more positive attitude towards the use of this drug than is expected by the physicians. About 90% of the patients appreciated their quality of life as excellent, very good, or good after 6 months of ENF treatment.
Keywords
Full Text
About the authors
Aleksey V. Kravchenko
Federal Scientific-and-Methodic Center for AIDS Prevention and Control; Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
Email: kravtchenko@hivrussia.net
Moscow
V. G Kanestri
Federal Scientific-and-Methodic Center for AIDS Prevention and Control; Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
Email: kanestry@yandex.ru
Moscow
References
- Покровский В.В., Юрин О.Г., Кравченко А.В. и др. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2012; 6, приложение. 28 с.
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents / Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) March 27, 2012 (http://AIDSinfo.nih.gov).
- Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 6,1; November, 2012). European AIDS Clinical Society (http://www. europeanaidsclinicalsociety.org).
- Бартлетт Д., Галлант Д., Фам П. Клинические аспекты ВИЧ-инфекции. М.: Р. Валент, 2012. 528 с.
- Katlama C., Haubrich R., Lalezari J. et al. Efficacy and safety of etravirine in treatmentexperienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23(17): 2289-2300.
- Clotet B., Bellos N., Molina J.M. et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369(9568): 1169-1178.
- Farthing C., Ward D., Hicks C., et al. Tipranavir/r demonstrates superior and durable treatment response compared with comparator PI/r in highly treatment experienced (HTE) patients: Week 96 RESIST 1 and 2 Results. 46th ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy). San Francisco, USA, 2006. Abstract H-1385.
- Кравченко А.В. Новые направления антиретровирусной терапии. Медицинская кафедра 2005; 3(15): 61-69.
- Arasteh R., Lazzarin A., Clotet B. et al. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. XV International AIDS Conference. Bangkok, Thailand, 2004. Abstract MoOrB1058.
- Fatkenheuer G., Nelson M., Lazzarin A., et al. Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection. New Engl. J. Med. 2008; 359(14): 1442-1455.
- Cooper D.A., Steigbigel R.T., Gatell J.M. et al. Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. New Engl. J. Med. 2008; 359(4): 355-365.
- Stanfield-Oakley SA. et al. 47th ICAAC, 2007. Poster H-1051.
- Кравченко А.В., Голохвастова Е.Л., Виноградова Е.Н. и др. Высокоактивная антиретровирусная терапия у больных ВИЧ-инфекцией с множественной резистентностью ВИЧ к антиретровирусным препаратам. Эпидемиол. и инфекц. бол. 2008; 3: 51-54.
- Elzi L., Kaufmann G., Weber R. et al. Discontinuation of Enfuvirtide in Heavily Pretreated HIV-infected Individuals. HIV Clin. Trials. 2009; 10(4): 207-214.
- Bonora S., Calcagno A., Cometto C. at al. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. Infection 2012; 40(1): 69-75.
- Кравченко А.В., Кузнецова А.В., Козырев О.А. и др. Ингибитор слияния энфувиртид в схемах АРВТ у больных с ВИЧ-инфекцией и туберкулезом. ВИЧ-инфекция и иммуносупрессии 2010; 2(4): 35-41.
- Horne R., Kovacs C., Katlama C. et al. Prescribing and using self-injectable antiretrovirals: How concordant are physician and patient perspectives? AIDS Research and Therapy 2009, 6:2 doi: 10.1186/1742-6405-6-2.
- Pulido F., Del Pozo M.A., Fernández-Guerrero M. et al., Patients’ Perception and Effectiveness of a Treatment Containing Enfuvirtide When Used in HIV-Infected Patients Without Very Advanced Disease. HIV Clin. Trials 2008; 9(2): 83-90.
Supplementary files
